Novartis expands cancer immunotherapy research program with acquisition of CoStim

February 17, 2014 Acquisition adds novel immune modulating targets and technology to accelerate Novartis cancer immunotherapy program Novartis and University of Pennsylvania CAR immunotherapy research combined with CoStim targets and technology strengthens Novartis’ position in cancer immunotherapy discovery Novartis announced today that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc., a Cambridge, MA-based, …